Pharmamarketeer

Roche’s Tecentriq scores a first-in-class double win in new liver cancer patients

Roche is out in full force with Tecentriq results in liver cancer. The immuno-oncology med, in combination with fellow Roche drug Avastin, not only showed it could beat Bayer’s standard-of-care Nexavar at stalling cancer progression in previously untreated patients. It extended their lives, too.

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl